Waldenström’s macroglobulinemia

Janssen gets EC approval for two new indications of Imbruvica
Pharmaceutical Business Review
Wed, 08/14/19 - 10:17 am
JNJ
Janssen
Europe
Imbruvica
Waldenström’s macroglobulinemia
chronic lymphocytic leukemia
Upcoming events – Crucial data on zanubrutinib and filgotinib approach
EP Vantage
Fri, 06/14/19 - 10:14 am
BeiGene
Waldenström’s macroglobulinemia
zanubrutinib
Galapagos
filgotinib
CLE
Sjögren’s syndrome
Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Endpoints
Mon, 08/27/18 - 10:02 am
AbbVie
JNJ
FDA
Imbruvica
Rituxan
Roche
AstraZeneca
non-Hodgkin's lymphoma
Waldenström’s macroglobulinemia